Zusammenfassung
Ein besseres Verständnis der für die Prostatakarzinomentstehung wichtigen Signaltransduktoren und Genregulatoren wird zur Entwicklung neuer diagnostischer und prognostischer Biomarker führen, mit deren Hilfe der individuelle Verlauf eines Prostatakarzinoms besser vorherzusagen ist. Darüber hinaus werden detailliertere Kenntnisse über dysregulierte Gene die Entwicklung spezifischer niedermolekularer Wirkstoffe ermöglichen, die ähnlich wie bereits bei anderen Tumorentitäten, gezielte Therapieansätze denkbar werden lassen. Die bisherigen Arbeiten der Bonner Forschergruppen überzeugten im Wettbewerb um eine von der Rudolf-Becker-Stiftung im Stifterverband der Deutschen Wissenschaft geförderten Stiftungsprofessur, die angesiedelt im ebenfalls von der Deutschen Krebshilfe unterstützen „Centrum für integrierte Onkologie“ die Keimzelle für eine effektive, grundlagenorientierte Forschung auf diesem Gebiet werden soll.
Abstract
A better understanding of signal transduction and gene regulation during prostate carcinogenesis will allow the development of novel diagnostic and prognostic biomarkers and a better prediction of the individual course of prostate cancer disease. It will also enhance the design and development of specific small molecular components aiming for specific therapies. The research groups in Bonn succeeded in the competition for an endowed professorship supported by the Rudolf Becker Stiftung (German Science Endowment Fund) settled in the“Centrum für integrierte Onkologie” funded by the German Cancer Aid. This should be the perfect breeding ground for future research in the field of prostate cancer.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Bastian PJ, Ellinger J, Wellmann A et al. (2005) Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 11: 4097–4106
Bastian PJ, Ellinger J, Schmidt D et al. (2004) GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age? Eur J Med Res 9: 523–527
Bastian PJ, Ellinger J, Heukamp LC et al. (2007) Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 51: 665–674
Ellinger J, Bastian PJ, Jurgan T et al. (2008) CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71: 161–167
Ellinger J, Bastian PJ, Haan KI et al. (2008) Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer 122: 138–143
Ellinger J, Haan K, Heukamp LC et al. (2008) CpG Island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 68: 42–49
Ellinger J, Mueller SC, Wernert N et al. (2008) Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence following prostatectomy. BJU Int (in press)
Bastian PJ, Palapattu GS, Yegnasubramanian S et al. (2007) Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res 13: 5361–5367
Bastian PJ, Palapattu GS, Lin X et al. (2005) Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11: 4037–4043
Kahl P, Gullotti L, Heukamp LC et al. (2006) Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 66: 11341–11347
Metzger E, Wissmann M, Yin N et al. (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437: 436–439
Muller JM, Metzger E, Greschik H et al. (2002) The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. EMBO J 21: 736–748
Wissmann M, Yin N, Muller JM et al. (2007) Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 9: 347–353
Hugel A, Wernert N (1999) Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer. Br J Cancer 79: 551–557
Kaminski A, Hahne JC, Haddouti EM et al. (2006) Tumour stroma interactions between metastatic prostate cancer cells and fibroblasts. Int J Mol Med 18: 941–950
Wernert N, Raes MB, Lassalle P et al. (1992) c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am J Pathol 140: 119–127
Wernert N, Gilles F, Fafeur V et al. (1994) Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. Cancer Res 54: 5683–5688
Hahne JC, Okuducu AF, Kaminski A et al. (2005) Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene 24: 5384–5388
Hahne JC, Fuchs T, El Mustapha H et al. (2006) Expression pattern of matrix metalloproteinase and TIMP genes in fibroblasts derived from Ets-1 knock-out mice compared to wild-type mouse fibroblasts. Int J Mol Med 18: 153–159
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ellinger, J., von Rücker, A., Wernert, N. et al. Prostatakarzinomforschung. Urologe 47, 1190–1192 (2008). https://doi.org/10.1007/s00120-008-1833-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-008-1833-z